Novel role of vascular smooth muscle cell-expressed METTL3 in atherosclerosis.
No abstract available
CommentOn
Cardiovasc Res. 2025 May 6;121(4):568-584. doi: 10.1093/cvr/cvaf029.
COI Statement
Conflict of interest: none declared.
References:
Brown JC, Gerhardt TE, Kwon E. Risk Factors for Coronary Artery Disease. Treasure Island, FL: StatPearls; 2024.
Yap C, Mieremet A, de Vries CJM, Micha D, de Waard V. Six shades of vascular smooth muscle cells illuminated by KLF4 (Krüppel-Like Factor 4). Arterioscler Thromb Vasc Biol 2021;41:2693–2707.
Jian D, Wang Y, Jian L, Tang H, Rao L, Chen K, Jia Z, Zhang W, Liu Y, Chen X, Shen X, Gao C, Wang S, Li M. METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications. Theranostics 2020;10:8939–8956.
Li Q, Yu L, Gao A, Ren R, Zhang J, Cao L, Wang X, Liu Y, Qi W, Cai L, Li W, Wang W, Guo X, Su G, Yu X, Zhang J, Xi B, Zhang Y, Zhang M, Zhang C. METTL3 (methyltransferase like 3)-dependent N6-methyladenosine modification on Braf mRNA promotes macrophage inflammatory response and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2023;43:755–773.
Dong Z, Jin Y, Shen Y, Huang J, Tan J, Feng Q, Gong Z, Zhu S, Chen H, Yu F, Li W, Jia Y, Kong W, Fu Y. Methyltransferase-like 3–catalysed N6-methyladenosine methylation facilitates the contribution of vascular smooth muscle cells to atherosclerosis. Cardiovasc Res 2025;121:568–584.